interleukin 2 inhibitor

MW 11,000 t0 12,000; inhibits IL-2 but not IL-3-dependent proliferation

Also Known As:

IL-2 inhibitor; interleukin-2 inhibitor

Networked: 17 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Intercellular Signaling Peptides and Proteins: 29768
    - Cytokines: 164289
      - Lymphokines: 811
        interleukin 2 inhibitor: 17
- Peptides: 82426
  - Intercellular Signaling Peptides and Proteins: 29768
    - Cytokines: 164289
      - Lymphokines: 811
        interleukin 2 inhibitor: 17
Biological Factors: 2472
- Intercellular Signaling Peptides and Proteins: 29768
  - Cytokines: 164289
    - Lymphokines: 811
      - interleukin 2 inhibitor: 17

Experts

1.	Antonelli, B: 1 article (07/2017)
2.	Caccamo, L: 1 article (07/2017)
3.	Cavenago, M: 1 article (07/2017)
4.	Dondossola, D: 1 article (07/2017)
5.	Maggi, U: 1 article (07/2017)
6.	Reggiani, P: 1 article (07/2017)
7.	Rossi, G: 1 article (07/2017)
8.	Bardenstein, R: 1 article (09/2006)
9.	Granot, E: 1 article (09/2006)
10.	Yakobovich, E: 1 article (09/2006)

Related Diseases

1.	Rheumatoid Arthritis 11/01/1995 - "IL-2 production by the phytohemaglutinin (PHA)-stimulated mononuclear cells (MNC) of peripheral blood (PB) and synovial fluid (SF) from patients with rheumatoid arthritis (RA), other arthritic diseases (OAD) and age-matched normal controls were studied, and the activity of IL-2 inhibitor in sera of studied subject was examined. " 01/01/1990 - "Interleukin-2 inhibitor in rheumatoid arthritis synovial fluid does not inhibit mononuclear cell responses to mitogens." 12/01/1988 - "Interleukin-2 inhibitor and measurement of interleukin-2 in synovial fluid of patients with rheumatoid arthritis." 11/01/1988 - "Multiple cytokine activities and loss of interleukin 2 inhibitor in synovial fluids of patients with rheumatoid arthritis." 08/01/1986 - "Since connective tissue diseases are often associated with deficient CMI responses, we examined the levels of IL-2 inhibitor in 26 systemic lupus erythematosus (SLE) and 22 rheumatoid arthritis (RA) patients. "
2.	Neoplasms (Cancer) 07/01/1988 - "IL-2 inhibitor activity of the sera from the tumor-bearers was greater than that of normal rats, while it was depressed markedly by cyclophosphamide (60 mg/kg i.p.). " 04/15/1988 - "IL-2 inhibitor activity of the sera from the tumor-bearing rats was greater than that of normal rats (P less than 0.001), but it was depressed markedly by cyclophosphamide (P less than 0.01). "
3.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 03/01/1988 - "Decreased activity of interleukin-2 inhibitor in plasma of patients with systemic lupus erythematosus." 08/01/1986 - "Since connective tissue diseases are often associated with deficient CMI responses, we examined the levels of IL-2 inhibitor in 26 systemic lupus erythematosus (SLE) and 22 rheumatoid arthritis (RA) patients. "
4.	Arthritis (Polyarthritis) 01/01/1989 - "[Prognostic value of an interleukin 2 inhibitor present in the synovial fluid in rheumatoid polyarthritis]." 07/01/1989 - "We conclude that IL-2 abnormalities appear to be most pronounced in RA compared with other inflammatory arthritides and that these changes do not appear to be directly related to serum or SF IL-2 inhibitor levels."
5.	Interstitial Cystitis (Interstitial Cystitis, Chronic) 05/01/1991 - "Urinary interleukin-2 inhibitor and the voiding symptoms in women patients with interstitial cystitis."

Related Drugs and Biologics

1.	Interleukin-2 (IL2)
2.	Cyclophosphamide (Cytoxan)
3.	Tacrolimus (Prograf)
4.	Cytokines
5.	Interleukin-2 Receptors (IL 2 Receptor)
6.	Nifedipine (Adalat)
7.	Mitogens
8.	Immunosuppressive Agents (Immunosuppressants)
9.	Antigens

Related Therapies and Procedures

1.	Therapeutics